Lack of effect of terfenadine on the pharmacokinetics of the CYP3A4 substrate buspirone

Pharmacology and Toxicology

Volumn 84, Issue 4, 1999, Pages 165-169

  Lamberg, Tommi S ^a   Kivistö, Kari T ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CYTOCHROME P450 INHIBITOR; TERFENADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL;

EID: 0032945121     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1999.tb00894.x     Document Type: Article

References (21)

1. Backman, J. T., K. T. Olkkola & P. J. Neuvonen: Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Therap. 1996, 59, 7-13.
2. Brion, N., E. Naline, D. Beaumont, M. Pays & C. Advenier: Lack of effect of terfenadine on theophylline pharmacokinetics and metabolism in normal subjects. Brit. J. Clin. Pharmacol. 1989, 27, 391-395.
3. Coniglio, A. A., W. R. Garnett, J. H. Pellock, O. Tsidonis, C. D. Hepler, R. Serafin, R. E. Small, S. M. Driscoll & H. T. Karnes; Effect of acute and chronic terfenadine on free and total serum phenytoin concentrations in epileptic patients. Epilepsia 1989, 30, 611-616.
4. Del Carpio, J., L. Kabbash, Y. Turenne, M. Prevost, J. Hebert, P. M. Bedard, M. Nedilski, A. Gutkowski & J. Schulz: Efficacy and safety of loratadine (10 mg once daily), terfenadine (60 mg daily), and placebo in the treatment of seasonal allergic rhinitis. J. Allergy Clin. Immunol. 1989, 84, 741-746.
5. Eller, M. G. & R. A. Okerholm: Pharmacokinetic interaction between terfenadine and ketoconazole. Clin. Pharmacol. Therap. 1991, 49, 130.
6. Gaillard, Y., J. P. Gay-Montchamp & M. Ollagnier: Simultaneous screening and quantitation of alpidem, zolpidem, buspirone and benzodiazepines by dual-channel gas chromatography using electron capture and nitrogen-phosphorous detection after solid-phase extraction. J. Chromatogr. 1993, 622, 197-208.
7. Gammans, R. E., R. F. Mayol & J. A. LaBudde: Metabolism and disposition of buspirone. Amer. J. Med. 1986, 80(suppl 3B), 41-51.
8. Goa, K. L. & A. Ward; Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986, 32, 114-129.
9. Honig, P. K., D. C. Wortham, K. Zamani, D. P. Conner, J. C. Mullin & L. R. Cantilena: Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993, 269, 1513-1518.
10. Jajoo, H.K., R. F. Mayol, J. A. LaBudde & I. A. Blair: Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab. Dispos. 1989, 17, 634-640.
11. Kishimoto, W., T. Hiroi, K. Sakai, Y. Funae & T. Igarashi: Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res. Comm. Mol. Pathol. Pharmacol. 1997, 98, 273-292.
12. Kivistö, K. T., P. J. Neuvonen & U. Klotz: Inhibition of terfenadine metabolism: pharmacokinetic and pharmacodynamic consequences. Clin. Pharmacokin. 1994, 27, 1-5.
13. Kivistö, K. T., T. S. Lamberg, T. Kantola & P. J. Neuvonen: Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin. Pharmacol. Therap. 1997, 62, 348-354.
14. Lamberg, T. S., K. T. Kivistö & P. J. Neuvonen: Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin. Pharmacol. Therap. 1998, 63, 640-645.
15. Luskin, S. S., W. E. Fitzsimmons, C. M. MacLeod & A. T. Luskin: Pharmacokinetic evaluation of the terfenadine-teophylline interaction. J. Allergy Clin. Immunol. 1989, 83, 406-411.
16. Mathews, D. R., B. McNutt, R. Okerholm, M. Flicker & G. McBride: Torsades de pointes occurring in association with terfenadine use. JAMA 1991, 266, 2375-2376.
17. Mayol, R. F., D. S. Adamson, R. E. Gammans & J. A. LaBudde: Pharmacokinetics and disposition of 14C-buspirone HCI after intravenous and oral dosing in man. Clin. Pharmacol. Therap. 1985, 37, 210.
18. McTavish, D., K. L. Goa & M. Ferril: Terfenadine: An updated review of its pharmacological properties and therapeutic efficacy. Drugs 1990, 39, 552-574.
19. Mäenpää, J., S. D. Hall, B. J. Ring, S. C. Storm & S. A. Wrighton: Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by α-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 1998, 8, 137-155.
20. Pohjola-Sintonen, S., M. Viitasalo, L. Toivonen & P. Neuvonen: Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur. J. Clin. Pharmacol 1993, 45, 191-193.
21. Rau, S. E., J. R, Bend, J. M. O. Arnold, L. T. Tran, J. D. Spence & D. G. Bailey: Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol. Therap. 1997, 61, 401-409.